Lymphocyte T-Cell Immune Modulator - Uses in Veterinary Medicine

Uses in Veterinary Medicine

LTCI is manufactured and distributed exclusively by T-Cyte Therapeutics, Inc. LTCI has been conditionally approved by the United States Department of Agriculture (USDA) as an aid in the treatment of cats infected with feline leukemia virus (FeLV) and/or feline immunodeficiency virus (FIV), and the associated symptoms of lymphopenia, opportunistic infection, anemia, granulocytopenia, or thrombocytopenia. Practitioners have successfully used LTCI in a number of problematic disease conditions affecting cats, dogs and horses, including:

• Feline Infections Peritonitis
• Feline Ocular Herpes
• Moderate to severe canine osteoarthritis
• Hemangiosarcoma
• Feline lower urinary tract disease
• Veterinarians, Horse Owners Look At Cat Treatment for Help with Equine Herpes Virus. LTCI (Lymphocyte T-Cell Immunomodulator), the first USDA-approved treatment for Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV), reported that LTCI may show promise in treating Equine Herpes Virus (EHV), the deadly disease attacking the nation’s equine industry.

The results from an early clinical trial conducted on twenty-one thoroughbred racehorses (fifteen suffering from chronic Exercise Induced Pulmonary Hemorrhage, six of whom were diagnosed with various forms of Upper Respiratory Disease) were impressive when judged by the effectiveness of the LTCI protein versus other products on the market used to treat horses with the illness. Six were foals suffering from forms of this life-threatening pneumonia, thought to be Rhodococcus or hemolytic Streptococcus.

Following LTCI treatment, all but one of the horses returned to work or racing, with none of the tracheal hemorrhaging that had plagued them. The researchers were really happy that five of the six gravely ill foals made uneventful recoveries. Unfortunately, the foal that died was beyond hope from the outset and was lost within 24 hours.

Veterinarians and pet owners from around the country, actually from around the world, have been reporting significant positive responses to LTCI. The one dispiriting element is when the disease processes are allowed to progress too far before treatment, leaving no hope for improvement. While LTCI is labeled for use for FeLV and FIV, once veterinarians understand LTCI’s mode of action and safety, practitioners envision the off-label potentials in treating other, equally cruel diseases. No adverse event has ever been reported following the use of LTCI and it is postulated that LTCI could benefit EHV cases as well as outbreaks of Canine Influenza. The early trial results are promising and very intriguing. Hopefully, a further trial will prove the potential of LTCI as a major medical breakthrough in the field of immunotherapy, not only as has been shown for cats, but also to help control other inflammatory diseases in dogs, including arthritis, and EPM, endotoxemia, and laminitis in horses.

The manufacturer encourages questions regarding the use of LTCI. Veterinarians may order LTCI at www.TCyte.com or by phone (1-800-483-2104). Streamlined ordering enables practitioners to quickly receive the most advanced product for the care and treatment of FeLV and/or FIV, of great significance in cases of critically ill patients.